Cerebral amyloid angiopathy — designated CAA, a progressive age-related cerebrovascular disorder caused by the pathological deposition of amyloid-beta (Aβ) peptide — principally Aβ40 — within the walls of small and medium-sized cortical and leptomeningeal arteries, arterioles, and capillaries, causing progressive vessel wall infiltration, smooth muscle cell loss, vessel fragility, and ultimately the spontaneous vessel rupture that produces the lobar intracerebral hemorrhage (ICH) that is CAA's most feared acute complication — is among the most clinically significant cerebrovascular diseases of advancing age, affecting an estimated 20–40% of individuals over 70 and more than 50% of those over 80 at autopsy-confirmed prevalence, with the risk increasing steeply with age, with APOE4 genotype (ε4 heterozygotes carry approximately 2–3× the population risk and ε4/ε4 homozygotes carry more than 5× the risk, with the APOE4 allele promoting both amyloid-beta production and impaired clearance along perivascular drainage pathways), and with prior lobar ICH (which predicts a recurrent ICH risk exceeding 10% per year in confirmed CAA, making secondary hemorrhage prevention a critical ongoing management priority); the clinical spectrum of CAA extends well beyond lobar ICH alone — cortical superficial siderosis (cSS), the accumulation of hemosiderin in the subarachnoid space and cortical surface from chronic microhemorrhages along leptomeningeal vessels, appears on MRI susceptibility-weighted imaging (SWI) and gradient echo (GRE) sequences as linear hypointensities tracing cortical gyri, and is a strong independent predictor of recurrent ICH and of the transient focal neurological episodes ("amyloid spells") that are pathognomonic of CAA — brief, stereotyped, spreading sensory or motor symptoms lasting seconds to minutes, beginning focally and spreading (Jacksonian march-like) across a body region, reflecting cortical spreading depolarization propagating across cortex rendered electrically unstable by superficial siderosis; lobar microbleeds — punctate cortical and subcortical hemosiderin deposits visible as hypointense foci on GRE/SWI with a lobar distribution (sparing the deep grey nuclei, thalamus, and brainstem where hypertensive vasculopathy tends to cluster) — accumulate progressively with CAA severity, with 10 or more lobar microbleeds conferring substantially elevated recurrent hemorrhage risk; white matter hyperintensities, cortical microinfarcts, enlarged perivascular spaces in the centrum semiovale, and progressive cortical atrophy from ischemic injury compound the neurocognitive burden, producing a cognitive decline trajectory progressing from mild cognitive impairment to CAA-associated dementia that is clinically distinct from — though frequently co-existing with — Alzheimer disease dementia, given that amyloid-beta accumulates in both parenchymal plaques (Alzheimer) and vessel walls (CAA), and the two conditions share the APOE4 genetic risk architecture; diagnosis in life rests upon the Boston Criteria v2.0 (2022 update incorporating cortical superficial siderosis as a major imaging marker), which classify probable CAA as: age ≥50, two or more lobar microbleeds, or one lobar ICH plus lobar microbleeds, or cortical superficial siderosis (focal or disseminated), with no other cause for the hemorrhagic pattern — the v2.0 criteria enable probable CAA diagnosis without tissue confirmation in the appropriate clinical and neuroimaging setting; treatment currently lacks any disease-modifying therapy specifically targeting CAA — management centers on strict blood pressure control (systolic target <130 mmHg), lifelong avoidance of anticoagulants and antiplatelet agents in all but the most compelling competing indication, fall prevention to reduce traumatic hemorrhage risk, cognitive support and dementia management, and — increasingly — amyloid-related imaging abnormalities (ARIA) monitoring for patients receiving anti-amyloid immunotherapy (lecanemab/Leqembi, donanemab/Kisunla) for early Alzheimer disease or CAA-associated dementia, because CAA patients on anti-amyloid antibodies carry substantially elevated ARIA risk, with ARIA-E (vasogenic edema) and ARIA-H (new microbleeds and hemosiderin deposits) detected on serial MRI requiring rigorous protocol-driven surveillance before and during immunotherapy dosing to detect adverse imaging findings that may require dose interruption or discontinuation; care technology platforms serve every dimension of CAA management from acute hemorrhage event documentation through longitudinal microbleed and siderosis burden surveillance, cognitive trajectory monitoring with validated instruments like the Montreal Cognitive Assessment (MoCA), anticoagulation and antiplatelet avoidance documentation, blood pressure control adherence tracking, fall prevention protocols, and the emerging ARIA surveillance workflows demanded by the integration of anti-amyloid immunotherapy into early CAA-associated dementia management.
Cerebral amyloid angiopathy technology platforms — encompassing the neurology and stroke emergency platforms where acute lobar ICH is identified on non-contrast CT and the clinical diagnosis of CAA is established by Boston Criteria v2.0 imaging criteria on MRI GRE and SWI sequences, the neuroradiology platforms that perform and report serial MRI microbleed counts, cortical superficial siderosis extent, white matter hyperintensity burden, and ARIA surveillance in patients on anti-amyloid immunotherapy, the neuropsychology and cognitive assessment platforms that administer and trend MoCA scores and formal neuropsychological testing batteries to quantify the CAA-associated cognitive decline trajectory, the neurology clinic and pharmacy platforms that document anticoagulant and antiplatelet avoidance decisions and blood pressure management adherence, the multidisciplinary care coordination platforms that manage fall prevention protocols, physical and occupational therapy integration, and home safety assessment across a cognitively vulnerable older patient population, and the specialty infusion center and imaging surveillance platforms managing the pre-dosing MRI ARIA checks and post-dosing safety imaging for patients receiving lecanemab or donanemab immunotherapy with known CAA — must maintain the availability and performance standards required by the acute hemorrhage event documentation urgency, the serial imaging burden surveillance precision, the cognitive trajectory monitoring continuity, the medication safety documentation obligations, and the ARIA surveillance protocol rigor that define modern evidence-based CAA management. This guide explains why cerebral amyloid angiopathy care tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the lobar hemorrhage event logging, MRI microbleed surveillance, MoCA cognitive tracking, anticoagulation avoidance documentation, blood pressure adherence monitoring, fall prevention coordination, and ARIA immunotherapy surveillance workflows that constitute best-practice CAA care.
Why Cerebral Amyloid Angiopathy Tech Platforms Require Specialized Monitoring Attention
Cerebral amyloid angiopathy management is defined by several compounding clinical risk domains that together make platform reliability a patient safety imperative rather than a service quality concern. The acute lobar ICH risk — with annual recurrence rates exceeding 10% in confirmed CAA after a first hemorrhage — means that the care platforms documenting anticoagulant avoidance decisions, blood pressure control adherence records, and hemorrhage event histories are not administrative tools but active components of hemorrhagic stroke risk reduction. A platform failure that disrupts documentation of a newly initiated anticoagulant in an emergency department setting for a CAA patient with atrial fibrillation — where the competing risks of ICH recurrence against cardioembolic stroke demand careful clinical documentation accessible to every treating physician — is a documentation gap with direct hemorrhage risk implications. The cognitive decline dimension of CAA creates an additional platform reliability pressure: patients managing progressive cognitive impairment depend more heavily on care coordination platforms, caregiver-facing communication tools, and structured cognitive surveillance systems, and are less able to compensate for platform failures by navigating alternative pathways. The ARIA monitoring urgency introduced by anti-amyloid immunotherapy adds a third high-stakes dimension: lecanemab and donanemab ARIA surveillance requires serial pre- and post-dosing MRI result delivery to the treating neurologist within a clinical window that determines whether the next immunotherapy dose can proceed, meaning MRI result delivery platform failures directly obstruct the dosing decision workflow.
CAA care platforms also carry the particular monitoring challenge of longitudinal imaging surveillance continuity. Unlike acute care platforms where a failure is clinically obvious at the point of care, serial MRI microbleed count comparison platforms and cortical superficial siderosis progression records can fail silently — an imaging platform failure that prevents the upload or retrieval of a 6-month follow-up SWI series means that the neuroradiologist performing the annual burden comparison may be working with an incomplete image set, potentially underestimating microbleed burden progression or missing new cortical siderosis that would change the hemorrhage risk assessment and management intensity. Silent failures in longitudinal imaging platforms are clinically more dangerous than obvious outages because they do not trigger immediate clinical response; by the time the data gap is recognized, the clinical opportunity to act on the missing imaging finding has passed. Fall prevention and cognitive support platforms for CAA patients compound the risk further: the combination of cognitive impairment and high intracranial hemorrhage risk from fall-related head trauma makes fall prevention protocol platform availability a cerebrovascular safety concern with direct hemorrhage risk implications for a population for whom traumatic ICH may be indistinguishable from — and additive to — spontaneous CAA-related hemorrhage.
The intersection of CAA with anti-amyloid immunotherapy creates monitoring requirements without precedent in prior CAA care technology deployments. Pre-lecanemab and pre-donanemab CAA care did not require the serial MRI ARIA surveillance that now defines safe immunotherapy delivery in patients with concurrent CAA. The FDA labeling for both lecanemab and donanemab identifies CAA as a significant ARIA risk amplifier — patients with more than four lobar microbleeds at baseline carry substantially elevated ARIA-H risk, and clinical trial safety data demonstrate that APOE4/ε4 homozygotes on anti-amyloid antibodies have ARIA rates exceeding 40% for ARIA-E and ARIA-H combined. The surveillance MRI workflow — baseline MRI before initiation, post-infusion monitoring MRIs at defined intervals, enhanced monitoring MRI scheduling upon any symptom suggestive of ARIA — must be supported by care platforms capable of reliably delivering imaging results, tracking ARIA severity grading (ARIA-E: mild/moderate/severe; ARIA-H: number and volume of new microbleeds/hemosiderin deposits), and triggering the dose-hold or dose-discontinuation workflow when ARIA exceeds protocol thresholds. These workflows require not only platform availability but reliable, auditable result delivery within the clinical decision window.
Lobar hemorrhage event documentation platforms cannot fail during acute stroke episodes or care transitions. When a CAA patient presents to the emergency department with an acute lobar ICH, the hemorrhage event record documenting the previous ICH history, anticoagulation status, blood pressure trajectory, and prior microbleed burden must be accessible to the emergency neurologist and neurosurgeon who are making acute management decisions. A care platform that is unavailable during the acute hemorrhage event deprives the clinical team of the longitudinal CAA context — prior lobar ICH count, antiplatelet use, blood pressure control history — that directly informs management decisions. Monitor lobar hemorrhage event log platforms at 1-minute intervals with 24/7 immediate alerting.
MRI microbleed and cortical superficial siderosis surveillance platforms support hemorrhage risk stratification. The serial SWI/GRE imaging burden record — the longitudinal documentation of lobar microbleed count progression and cortical siderosis extent — is the primary quantitative basis for CAA severity staging, Boston Criteria v2.0 classification, and hemorrhage risk stratification. Platform failures that prevent neuroradiologists from accessing prior-study microbleed counts for comparison, or that interrupt the structured reporting of new cortical siderosis, compromise the imaging-driven risk assessment that guides anticoagulant avoidance decisions, blood pressure target setting, and immunotherapy eligibility determination. Monitor imaging surveillance platforms at 1-minute intervals during clinical hours.
Cognitive function assessment platforms track the dementia trajectory and guide care planning. Serial MoCA scores and formal neuropsychological testing records document the cognitive decline trajectory associated with CAA — distinguishing stable mild cognitive impairment from progressive CAA-associated dementia, detecting the steeper decline that may prompt advance care planning conversations, and triggering referrals to memory care and social work services for patients who have crossed functional thresholds requiring care support escalation. Cognitive assessment platform failures that prevent MoCA score upload or trend visualization interrupt the longitudinal cognitive monitoring that guides clinical decision-making and care planning in a condition where cognitive decline often progresses insidiously.
ARIA surveillance MRI result delivery platforms are time-critical for anti-amyloid immunotherapy safety. For CAA patients on lecanemab or donanemab, the pre-dosing ARIA surveillance MRI result must be available to the treating neurologist before the scheduled infusion. An ARIA surveillance platform failure that delays the result delivery creates a dosing decision workflow obstruction — the neurologist cannot clear the patient for the next infusion without the surveillance MRI result, and proceeding with infusion in the absence of confirmed ARIA status carries the risk of administering an anti-amyloid antibody to a patient with undetected symptomatic ARIA, worsening the ARIA-E edema or expanding ARIA-H hemosiderin deposition. Monitor ARIA result delivery platforms at 1-minute intervals during clinical hours with immediate alerting.
What to Monitor on a Cerebral Amyloid Angiopathy Tech Platform
Lobar Hemorrhage Event Logs
Monitor lobar intracerebral hemorrhage event documentation records at the full depth of clinical content they carry: acute ICH presentation records (date, time, presenting symptoms, initial GCS, initial blood pressure at presentation, CT findings including hematoma location — lobar versus deep versus cerebellar, hematoma volume by ABC/2 or planimetric calculation, presence of intraventricular extension, midline shift), prior ICH history records (cumulative lifetime lobar ICH count, dates and locations of prior hemorrhages, prior hematoma volumes and expansion trajectories, functional outcomes from prior hemorrhages), hemorrhage recurrence risk documentation records (annual recurrence risk estimate based on Boston Criteria classification, lobar microbleed burden, cortical siderosis extent, APOE4 genotype status, blood pressure control trajectory, and anticoagulant or antiplatelet exposure history), acute management decision records (anticoagulant reversal if applicable — andexanet alfa for factor Xa inhibitors, idarucizumab for dabigatran, prothrombin complex concentrate for warfarin, blood pressure management target and agent used during acute hemorrhage, neurosurgical consultation documentation, intracranial pressure management if applicable), and discharge hemorrhage management plan records (blood pressure target post-discharge, anticoagulant and antiplatelet avoidance instruction documentation, fall prevention referral, neurology follow-up plan, repeat imaging schedule) at 1-minute intervals, 24/7. Alert immediately — a lobar hemorrhage event log platform that fails at 11:40 PM when an emergency neurologist at a community hospital is attempting to access the ICH recurrence history of a 74-year-old APOE4 carrier with confirmed CAA who has been brought in after his third potential lobar ICH disrupts the longitudinal hemorrhage history access that directly informs the acute management approach, the neurosurgical consultation threshold decision, and the blood pressure management intensity that distinguishes CAA-related ICH management from hypertensive basal ganglia hemorrhage management.
MRI Microbleed and Cortical Superficial Siderosis Burden Surveillance
Monitor MRI microbleed and cortical superficial siderosis burden surveillance records at the full imaging protocol granularity they require: baseline SWI/GRE microbleed characterization records (total lobar microbleed count at diagnosis or first imaging, microbleed topographic distribution — frontal, parietal, temporal, occipital, cerebellar lobar cortex and subcortex, documentation of absence of deep microbleeds or single deep microbleed permissible under Boston Criteria v2.0, first-imaging microbleed burden as the reference for all subsequent serial comparisons), serial microbleed count comparison records (interval new microbleed identification between serial SWI/GRE studies — 6-month and 12-month standard surveillance intervals in active CAA management, structured comparison against prior study with explicit enumeration of new versus previously documented microbleeds at each lobar location, documentation of uncertainty when image quality differences between serial studies limit definitive new-versus-old attribution), cortical superficial siderosis characterization records (focal cSS — one to two sulci involved, disseminated cSS — three or more sulci across at least two regions, cSS extent and topographic distribution at each imaging timepoint, interval progression from focal to disseminated cSS as a high-risk trajectory marker, sulcal blood degradation products on FLAIR in the subacute period), white matter hyperintensity burden records (Fazekas scale or volume measurement at serial timepoints, periventricular versus deep white matter distribution, confluent versus punctate pattern), enlarged perivascular space characterization in the centrum semiovale (a marker of impaired perivascular amyloid drainage) records, and annual structured imaging burden summary records used for Boston Criteria v2.0 classification and hemorrhage risk stratification at 1-minute intervals during neuroradiology and clinical operational hours. Alert immediately — serial imaging burden surveillance platform failures during the 12-month follow-up SWI comparison for a 77-year-old with probable CAA and nine baseline lobar microbleeds prevent the neuroradiologist from accessing the prior-study image set for side-by-side comparison, risk leaving new cortical siderosis progression undetected, and interrupt the structured imaging burden report that the managing neurologist uses to determine whether the annual microbleed count progression meets the threshold for escalated hemorrhage prevention counseling and antiplatelet withdrawal review.
Cognitive Function Assessments (MoCA Trends)
Monitor cognitive function assessment records at the full clinical scoring and trend analysis depth they support: MoCA administration records (Montreal Cognitive Assessment total score at each administration — 0 to 30 scale, cutoff of 26/30 for mild cognitive impairment, domain subscores across visuospatial and executive function, naming, attention and concentration, language, abstraction, delayed recall, and orientation — each domain capturing distinct cortical territory contributions relevant to the lobar distribution of CAA injury, MoCA education correction for individuals with 12 or fewer years of education, administration modality — in-clinic versus telephone versus MoCA-Blind versus digital remote administration with version documentation), serial MoCA trend records (score trajectory over time from CAA diagnosis or first cognitive concern, rate-of-change calculation between consecutive assessments, documentation of clinically meaningful decline — 2-point decrease considered significant, domain-specific decline pattern identifying dominant parietal versus frontal versus temporal involvement), formal neuropsychological testing records (comprehensive neuropsychological battery results when clinical progression warrants beyond-MoCA assessment — memory encoding versus retrieval dissociation distinguishing CAA-associated memory impairment from Alzheimer-pattern encoding failure, executive function battery results, processing speed, visuospatial function tests, gait and dual-task cognitive performance records), clinical cognitive staging records (CDR — Clinical Dementia Rating scale overall and sum-of-boxes scores at baseline and serial intervals, functional staging documentation — independent ADL versus instrumental ADL impairment versus requiring assistance with basic ADLs, transition from MCI to dementia clinical stage documentation), and care escalation trigger records (cognitive decline crossing functional threshold prompting memory care consultation, social work referral, advance care planning discussion initiation, driving safety evaluation referral, financial and legal affairs planning support engagement) at 1-minute intervals during clinical hours. Alert immediately — cognitive assessment platform failures that prevent MoCA score upload or trend display during a quarterly neurology visit for a 71-year-old with CAA-associated mild cognitive impairment interrupt the longitudinal score comparison that determines whether the patient's cognitive trajectory warrants initiation of advance care planning discussions and home safety assessment referral.
Anticoagulation and Antiplatelet Avoidance Documentation
Monitor anticoagulation and antiplatelet avoidance documentation records at the medication safety documentation depth required by the competing hemorrhagic and thrombotic risks in CAA: anticoagulant avoidance decision records (structured documentation of the clinical decision to withhold or discontinue anticoagulant therapy in CAA — the treating neurologist's documented assessment of hemorrhagic ICH recurrence risk versus competing thromboembolic indication such as atrial fibrillation, mechanical heart valve, venous thromboembolism, or hypercoagulable state; the shared decision-making conversation records with patient and family documenting that both the bleeding and clotting risks were explained; the structured risk-benefit documentation using published CAA recurrence risk estimates versus CHA2DS2-VASc score-derived stroke risk in AF; and the final anticoagulant-avoidance recommendation with the clinical rationale), antiplatelet exposure documentation records (aspirin, clopidogrel, ticagrelor, dipyridamole — structured documentation of prior antiplatelet use with dates of initiation and cessation, antiplatelet cessation decision documentation for patients with CAA where the hemorrhage risk is judged to outweigh the antiplatelet benefit, documentation of circumstances where antiplatelet continuation was judged necessary — recent coronary stent with drug-eluting stent drug-elution period requiring dual antiplatelet therapy, with the hemorrhage risk management approach), medication reconciliation alert records (electronic medication reconciliation flags triggered by anticoagulant or antiplatelet prescribing in a patient with active CAA diagnosis — the clinical decision support alert that should fire when warfarin, apixaban, rivaroxaban, dabigatran, edoxaban, aspirin, or clopidogrel is prescribed for a patient with CAA documented in the problem list), emergency department anticoagulation reversal records (documentation of anticoagulant reversal agent administered during acute ICH — andexanet alfa, idarucizumab, PCC — and subsequent anticoagulant-avoidance plan documented before discharge), and NSAID and thrombolytic contraindication records (documentation of the CAA contraindication to thrombolysis in presenting strokes, NSAIDs as relative contraindication in anticoagulant-free CAA management) at 1-minute intervals during clinical hours. Alert immediately — medication safety documentation platform failures during the emergency department evaluation of a 79-year-old with known CAA presenting with a new lobar ICH who is also on apixaban for atrial fibrillation interrupt the anticoagulant reversal documentation workflow and the subsequent structured anticoagulant-avoidance discharge documentation that prevents the prescribing of anticoagulation in the post-ICH period without explicit multidisciplinary risk-benefit reassessment.
Blood Pressure Control Adherence
Monitor blood pressure control adherence records at the clinical management depth required by the central role of hypertension control in CAA hemorrhage risk reduction: ambulatory blood pressure monitoring records (24-hour ABPM results — mean daytime systolic, mean nocturnal systolic, nocturnal dipping pattern — non-dipping nocturnal blood pressure pattern associated with increased CAA hemorrhage risk, white-coat versus masked hypertension classification, systolic variability assessment), office blood pressure records (bilateral upper extremity seated BP at each clinic visit, target systolic <130 mmHg documented in CAA management plans, documentation of at-target versus above-target classification at each encounter), home blood pressure monitoring records (patient-reported home BP log upload or connected home BP cuff data integration — morning and evening measurements, trend analysis, identification of hypertensive episodes >160 mmHg systolic requiring clinical contact), antihypertensive medication records (current antihypertensive regimen — agent, dose, frequency; medication adherence documentation; side effect and tolerability records; dose adjustment history with clinical rationale), blood pressure control trajectory records (systolic BP trend over the CAA management period — time-at-target percentage, proportion of readings above 130 mmHg, proportion above 150 mmHg — the threshold associated with sharply increased CAA hemorrhage risk in observational studies; and blood pressure control classification at each annual review as optimal, suboptimal, or inadequate with corresponding management intensification plan), and hypertensive urgency response records (acute management of BP >180/120 mmHg in an outpatient or emergency setting in a CAA patient, including agent used, response, and documentation of whether the episode was associated with hemorrhagic symptoms) at 1-minute intervals during clinical hours. Alert immediately — blood pressure monitoring adherence platform failures during a routine hypertension management visit for a 68-year-old with probable CAA and a history of one prior lobar ICH prevent the attending neurologist from accessing the home BP log data that determines whether the current antihypertensive regimen is achieving the <130 mmHg systolic target that is the most evidence-supported modifiable risk factor for CAA hemorrhage recurrence.
Fall Prevention Protocols
Monitor fall prevention protocol records across the full care coordination scope required by the dual cognitive-hemorrhagic risk that CAA imposes on fall safety: fall risk assessment records (validated fall risk instrument scores — Morse Fall Scale, Hendrich II Fall Risk Model, or STRATIFY tool — at initial assessment and at specified reassessment intervals, documentation of CAA-specific fall risk amplifiers including cognitive impairment severity, gait instability from white matter disease, orthostatic hypotension from antihypertensive medication, polypharmacy fall risk contribution, and visual disturbances from posterior cortical CAA involvement), environmental safety assessment records (occupational therapy home safety evaluation — removal of fall hazards, grab bar installation, non-slip surfaces, improved lighting, stair handrail assessment, bath and shower safety modifications), adaptive equipment records (mobility aid assessment — cane, rollator, or walker appropriateness; hip protector recommendation documentation for patients with gait instability and high fall frequency; alert device and medical alert system prescription), physical therapy records (balance and gait rehabilitation program records, exercise prescription for fall prevention — evidence-based programs including Tai Chi balance programs, progressive resistance training, and dual-task walking training particularly relevant for cognitively impaired CAA patients whose dual-task gait deterioration predicts fall risk), caregiver and patient education records (fall prevention education documentation — what to do if fall occurs, when to call emergency services, head injury symptom recognition in a CAA patient for whom even moderate head trauma carries ICH risk), head injury symptom recognition instruction records (specifically tailored CAA education: any head trauma — even without loss of consciousness — warrants urgent CT evaluation given the elevated spontaneous and traumatic ICH risk in confirmed CAA, with documentation that this education was provided and understood), and fall event documentation records (documented fall occurrences — date, circumstances, resulting injuries, head trauma assessment performed, CT scan ordered if applicable, clinical response) at 2-minute intervals during clinical hours. Alert on sustained failures — fall prevention protocol platform failures that prevent occupational therapists from accessing the structured fall risk assessment for a 73-year-old CAA patient with MoCA 21/30 and a history of gait instability from periventricular white matter disease interrupt the coordinated fall prevention workflow that reduces the traumatic ICH risk compounding her already elevated spontaneous lobar hemorrhage risk.
ARIA Monitoring for Immunotherapy Candidates
Monitor ARIA surveillance records at the full protocol depth required for anti-amyloid immunotherapy safety in CAA patients: pre-immunotherapy eligibility screening records (baseline MRI SWI/GRE lobar microbleed count — FDA prescribing information thresholds: patients with more than 4 microbleeds or prior lobar ICH require enhanced safety discussion and individualized risk-benefit assessment; APOE4 genotype result for ARIA risk stratification; baseline cortical superficial siderosis characterization; clinical ARIA risk category assignment — standard versus high risk versus very high risk), pre-infusion surveillance MRI records (scheduled MRI per protocol — lecanemab FDA-approved schedule: MRI before infusion 1, 7, and 14, then every 6 months; donanemab protocol: MRI at baseline, month 3, month 6, and then every 6 months; structured radiological ARIA-E and ARIA-H reporting at each surveillance timepoint), ARIA-E characterization records (vasogenic edema location — lobar versus sulcal versus gyral, edema severity classification — mild: single region, <5 cm in any dimension; moderate: up to 3 regions but not the above; severe: more than 3 regions or symptomatic; associated sulcal FLAIR signal, clinical ARIA-E symptom documentation — headache, confusion, vision changes, gait instability), ARIA-H characterization records (new microbleeds or hemosiderin deposits appearing after immunotherapy initiation — count and location of ARIA-H lesions at each post-infusion surveillance MRI, comparison to baseline and prior surveillance MRI, severity classification — mild: less than 5 new microbleeds; moderate: 5 to 9; severe: 10 or more, or any superficial siderosis progression), dosing decision records (dose continuation, dose hold pending symptom resolution, or permanent dose discontinuation decision at each ARIA surveillance timepoint with the clinical rationale, ARIA severity grade, and symptom status at the time of the dosing decision documented), and ARIA resolution monitoring records (follow-up MRI confirming ARIA-E resolution before dose resumption, residual ARIA-H documentation at resolution timepoint, enhanced monitoring frequency after ARIA episode resolution) at 1-minute intervals during clinical hours. Alert immediately — ARIA surveillance result delivery platform failures for a 66-year-old APOE4/ε4 homozygote with early CAA-associated dementia receiving lecanemab who is scheduled for infusion 14 at 10:00 AM prevent the treating neurologist from accessing the surveillance MRI result from the prior day that must confirm ARIA-E and ARIA-H status before the infusion proceeds, creating a clinical obstruction that cannot be resolved by proceeding to infusion without the confirmed ARIA status — because the patient's APOE4/ε4 homozygote status places her in the highest ARIA risk category where undetected ARIA-E worsening from a successive antibody dose carries a risk of symptomatic — and potentially life-threatening — cerebral edema.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. CAA management coordinates across neurology (Boston Criteria v2.0 classification, hemorrhage recurrence risk counseling, immunotherapy candidacy assessment), neuroradiology (serial SWI/GRE microbleed burden reporting, ARIA surveillance imaging), neuropsychology (MoCA administration, formal neuropsychological testing, cognitive staging), pharmacy and specialty pharmacy (anticoagulant avoidance documentation, antihypertensive medication management, lecanemab or donanemab infusion scheduling), emergency medicine (acute lobar ICH management, anticoagulant reversal), occupational and physical therapy (fall prevention protocols, environmental safety assessment, gait rehabilitation), social work (cognitive support services, care coordination, advance care planning), and genetics (APOE4 genotype testing and counseling) — an authentication failure simultaneously blocks every member of this multidisciplinary team from accessing the shared longitudinal CAA record that coordinates hemorrhage prevention, imaging surveillance, cognitive monitoring, and immunotherapy safety across the care continuum.
SSL Certificates
Monitor SSL certificate expiry across all cerebral amyloid angiopathy care technology platforms — lobar hemorrhage event log portals, MRI microbleed burden surveillance and ARIA imaging platforms, MoCA and neuropsychological testing platforms, medication safety and anticoagulation avoidance documentation systems, blood pressure monitoring platforms, fall prevention and occupational therapy coordination portals, anti-amyloid immunotherapy management and infusion scheduling systems, and neurology clinic and patient communication portals. A certificate error affecting an ARIA surveillance imaging platform on the morning of a scheduled lecanemab infusion — preventing the neurologist from accessing the pre-infusion MRI result that must confirm ARIA clearance before the dose proceeds — is a patient safety failure with direct immunotherapy management consequences. Monitor all SSL certificates daily with 30-day advance warning.
HIPAA and Neurovascular Data Considerations
Cerebral amyloid angiopathy care technology platforms handle a concentrated set of highly sensitive protected health information categories whose combination creates an elevated HIPAA Security Rule compliance profile: neuroimaging data (MRI SWI/GRE series documenting the lobar microbleed burden and cortical superficial siderosis extent that constitute the imaging hallmarks of probable CAA under Boston Criteria v2.0 — detailed brain anatomy imaging that is inherently re-identifiable even without embedded metadata), genetic information (APOE4 genotype results for hemorrhage risk stratification and immunotherapy ARIA risk classification — heritable genetic information subject to GINA protections in addition to HIPAA Privacy Rule obligations, with direct family planning and insurance discrimination risk implications), cognitive and neuropsychological testing records (serial MoCA scores and formal neuropsychological battery results documenting progressive cognitive decline toward dementia — among the most sensitive categories of mental health and cognitive status PHI, affecting employment, driving licensure, financial competency determinations, and advance directive planning), hemorrhage event records (acute lobar ICH documentation including clinical presentation severity, neurological deficits, and neurosurgical management decisions — acute-care records with the highest sensitivity classification), and anti-amyloid immunotherapy dosing and ARIA surveillance records for patients receiving lecanemab or donanemab (infusion records, ARIA grading, dose modification decisions — records whose availability must be preserved for both clinical safety and regulatory compliance given that ARIA adverse event documentation feeds post-marketing pharmacovigilance requirements). Platform availability monitoring provides the operational audit trail that demonstrates Security Rule-compliant system management.
The longitudinal nature of CAA monitoring — with serial MRI imaging records extending across years or decades of disease surveillance, cognitive assessment scores tracked from mild cognitive impairment through progressive dementia, and hemorrhage event records accumulating across multiple acute hospitalizations — means that HIPAA breach risk is compounded by the irreplaceable, longitudinally generated nature of the data. A breach of a CAA patient's serial MRI neuroimaging, cognitive trajectory, APOE4 genotype, and lobar ICH history simultaneously exposes acute-care records, genetic information, mental health and cognitive status records, and long-term neurological care records. Business Associate Agreements must cover every platform component in the CAA care technology stack — from the neuroradiology PACS system storing serial SWI/GRE images to the cognitive testing platform hosting MoCA scores to the specialty pharmacy system managing lecanemab infusion scheduling. Uptime monitoring records provide the availability documentation that supports HIPAA Security Rule compliance reporting and demonstrates operational reliability to compliance auditors and institutional partners.
Platforms supporting anti-amyloid immunotherapy ARIA surveillance carry additional regulatory documentation obligations beyond HIPAA: lecanemab and donanemab ARIA adverse event records feed FDA MedWatch post-marketing safety reporting requirements, and platforms managing ARIA grading records and dose modification decisions must maintain audit-ready documentation integrity. Availability monitoring evidence that demonstrates uninterrupted ARIA surveillance platform operation during active immunotherapy treatment periods supports both clinical safety documentation and post-marketing pharmacovigilance compliance.
Alerting Strategy for Cerebral Amyloid Angiopathy Tech Platforms
Immediate 24/7 alerting for authentication and lobar hemorrhage event log platforms: Authentication failures block all clinical team access simultaneously; lobar hemorrhage event log failures during acute ICH presentation are patient safety events that cannot wait for business-hours response. Neither has an acceptable window of unavailability.
Immediate clinical-hours alerting for MRI microbleed burden and ARIA surveillance platforms: Serial SWI/GRE comparison records and ARIA surveillance MRI result delivery platforms support active clinical decisions — both imaging burden progression risk stratification and immunotherapy dose-clearance decisions — that cannot be deferred pending platform restoration.
Immediate clinical-hours alerting for cognitive function assessment platforms: Serial MoCA trend platforms inform care escalation decisions during active neurology clinic visits; platform failures during scheduled cognitive assessments interrupt the longitudinal monitoring workflow.
Immediate clinical-hours alerting for anticoagulation and antiplatelet avoidance documentation platforms: Medication safety documentation failures in the context of competing hemorrhagic and thromboembolic risk management have direct patient safety implications; these platforms must be available during every clinical encounter where anticoagulant prescribing decisions are made.
Immediate clinical-hours alerting for blood pressure control adherence platforms: Antihypertensive management is the primary modifiable hemorrhage risk reduction intervention in CAA; BP monitoring adherence platform failures during clinical management visits interrupt the only evidence-based hemorrhage prevention monitoring workflow.
Immediate clinical-hours alerting for ARIA-H and ARIA-E surveillance result delivery platforms: Pre-infusion ARIA status confirmation is a mandatory safety gate for anti-amyloid immunotherapy dosing; result delivery platform failures directly obstruct the dosing decision workflow and cannot be resolved by proceeding without confirmed ARIA status.
Sustained-failure alerting (10–15 minutes) for fall prevention protocol platforms: Fall prevention workflows are clinically important but tolerate a brief latency before escalation; alert after 10–15 minutes of continuous unavailability during clinical hours.
30-day advance warning for all SSL certificates: Certificate expiry affecting ARIA surveillance or acute hemorrhage documentation platforms is a patient safety event; early warning is essential.
Vigilmon's multi-region monitoring confirms CAA platform availability from the geographies where neurology stroke centers, neuroradiology programs, neuropsychology clinics, and anti-amyloid immunotherapy infusion centers serve the predominantly older adult CAA patient population.
Status Page for Cerebral Amyloid Angiopathy Care Team Communication
A real-time status page gives neurology stroke clinic physicians tracking hemorrhage recurrence risk, neuroradiologists performing serial SWI/GRE microbleed burden comparisons, neuropsychologists administering MoCA and formal neuropsychological batteries, emergency physicians managing acute lobar ICH presentations, specialty pharmacists coordinating lecanemab and donanemab infusion schedules and ARIA surveillance MRI results, occupational therapists executing fall prevention protocols, and anti-amyloid immunotherapy safety coordinators managing ARIA grading and dose-hold workflows immediate visibility into platform status without requiring inbound IT support contact during time-sensitive clinical operations. Include the status page URL in lecanemab and donanemab infusion center contingency procedures, acute stroke unit clinical downtime protocols, neuroradiology ARIA surveillance MRI backup workflows, and CAA clinic care coordination materials so that all clinical team members know where to find real-time platform status information during any incident.
Vigilmon Setup for Cerebral Amyloid Angiopathy Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Lobar hemorrhage event logs and acute ICH records | 1 min | Slack + PagerDuty (24/7) | | MRI microbleed burden tracking platforms | 1 min | Slack + PagerDuty (clinical hours) | | Cortical superficial siderosis surveillance records | 1 min | Slack + PagerDuty (clinical hours) | | SWI/GRE microbleed count comparison records | 1 min | Slack + PagerDuty (clinical hours) | | MoCA and cognitive assessment score records | 1 min | Slack + PagerDuty (clinical hours) | | Anticoagulant and antiplatelet avoidance documentation | 1 min | Slack + PagerDuty (clinical hours) | | Blood pressure monitoring adherence records | 1 min | Slack + PagerDuty (clinical hours) | | Fall risk assessment and prevention protocol platforms | 2 min | Slack (clinical hours) | | ARIA-E and ARIA-H surveillance MRI result delivery | 1 min | Slack + PagerDuty (clinical hours) | | Anti-amyloid immunotherapy dosing records (if applicable) | 1 min | Slack + PagerDuty (clinical hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 PagerDuty alerting — an authentication failure simultaneously locks out every member of the CAA multidisciplinary team
- Configure lobar hemorrhage event log platforms with 24/7 immediate PagerDuty alerting — acute ICH presentations occur at all hours and the longitudinal hemorrhage record must be available to the emergency neurologist at 2:00 AM as reliably as at 2:00 PM
- Add MRI microbleed burden tracking platforms at 1-minute intervals with immediate clinical-hours alerting
- Configure cortical superficial siderosis surveillance records and SWI/GRE comparison platforms with clinical-hours immediate alerting — serial imaging burden comparison is the primary radiological risk stratification tool in CAA management
- Add MoCA and cognitive assessment score platforms at 1-minute intervals with immediate clinical-hours alerting
- Configure anticoagulant and antiplatelet avoidance documentation platforms with immediate clinical-hours alerting — medication safety documentation in the context of competing hemorrhagic and thromboembolic risk management has direct patient safety implications
- Add blood pressure monitoring adherence platforms at 1-minute intervals with immediate clinical-hours alerting — antihypertensive control is the most evidence-supported hemorrhage risk reduction intervention in CAA
- Configure fall risk assessment and prevention protocol platforms at 2-minute intervals with sustained-failure clinical-hours alerting
- Add ARIA-E and ARIA-H surveillance MRI result delivery platforms at 1-minute intervals with immediate clinical-hours alerting — pre-infusion ARIA confirmation is a non-negotiable dosing safety gate for lecanemab and donanemab
- Configure anti-amyloid immunotherapy dosing records at 1-minute intervals with immediate clinical-hours alerting for all practices with active CAA patients receiving immunotherapy
- Enable SSL certificate monitoring across all lobar ICH documentation, MRI microbleed surveillance, cognitive assessment, medication safety, blood pressure management, fall prevention, and ARIA monitoring platforms with 30-day advance email warning
Conclusion
Cerebral amyloid angiopathy care technology platforms are embedded in clinical decisions where a lobar hemorrhage event log platform unavailable at 1:20 AM when a vascular neurology fellow at a tertiary stroke center is evaluating a 76-year-old APOE4/ε4 heterozygote presenting with acute right parietal lobar ICH — who requires urgent access to the patient's documented prior hemorrhage history (one prior left frontal lobar ICH four years ago, the combined two lobar ICHs meeting Boston Criteria v2.0 for probable CAA), anticoagulation status (apixaban initiated for atrial fibrillation six months ago, requiring andexanet alfa reversal coordination), and blood pressure trajectory (systolic averaging 148 mmHg over the prior three months despite dual antihypertensive therapy, the suboptimal control documented in the BP adherence platform that cannot now be accessed) — leaves the fellow without the longitudinal CAA context that transforms a seemingly straightforward hypertensive ICH into a high-recurrence-risk probable CAA hemorrhage requiring explicitly documented anticoagulant avoidance planning before discharge; where an ARIA surveillance result delivery platform failure on the morning of a scheduled lecanemab infusion for a 64-year-old ε4/ε4 homozygote with early CAA-associated dementia — when the prior-day surveillance MRI result confirming ARIA-E and ARIA-H status must be available to the treating neurologist before the 9:00 AM infusion to determine whether the patient meets the dose-continuation criteria or requires a dose hold for newly detected asymptomatic ARIA-E — forces a clinical decision between canceling the infusion and delaying the patient's immunotherapy trajectory, or proceeding without confirmed ARIA status in the highest-risk genetic ARIA subgroup where undetected symptomatic ARIA-E may represent a life-threatening cerebral edema risk; and where an MRI microbleed burden comparison platform failure during the 12-month surveillance imaging review for a 70-year-old with disseminated cortical superficial siderosis and 11 lobar microbleeds on baseline SWI — who has been asking about low-dose aspirin for secondary cardiovascular prevention and whose antiplatelet avoidance recommendation depends critically on whether the serial microbleed count has progressed to 14 or more, crossing the threshold where even low-dose aspirin is judged to confer net hemorrhagic harm — prevents the neuroradiologist from performing the structured prior-versus-current microbleed comparison that the neurologist needs to complete the shared decision-making conversation about aspirin with this patient and his family. Lobar hemorrhage event documentation unavailable during an acute ICH presentation, ARIA surveillance result delivery blocked on the morning of an anti-amyloid immunotherapy infusion, serial microbleed comparison interrupted during the imaging review that determines antiplatelet safety — these are not IT incidents. They are clinical disruptions in the management of a progressive cerebrovascular disease whose annual hemorrhage recurrence rate, ARIA immunotherapy risk, cognitive decline trajectory, and medication safety complexity make platform availability a patient safety obligation at every point in the care continuum.
Uptime monitoring gives cerebral amyloid angiopathy tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to vascular neurology stroke programs, neuroradiology surveillance services, neuropsychology cognitive monitoring programs, anti-amyloid immunotherapy infusion centers, specialty pharmacies managing lecanemab and donanemab workflows, and HIPAA compliance auditors that platform operational reliability matches the hemorrhage prevention precision, ARIA surveillance rigor, cognitive monitoring continuity, and medication safety documentation intensity of modern evidence-based CAA management.
Start monitoring your cerebral amyloid angiopathy care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #CerebralAmyloidAngiopathy #CAA #AmyloidBeta #LobarHemorrhage #ARIA #Microbleeds #CorticalSuperficialSiderosis #MoCA #CognitiveDecline #AntiAmyloidTherapy #APOE4 #HIPAA #healthtech #digitalhealth #uptime #sre